JP6267412B2 - cAMP産生抑制剤 - Google Patents
cAMP産生抑制剤 Download PDFInfo
- Publication number
- JP6267412B2 JP6267412B2 JP2012007433A JP2012007433A JP6267412B2 JP 6267412 B2 JP6267412 B2 JP 6267412B2 JP 2012007433 A JP2012007433 A JP 2012007433A JP 2012007433 A JP2012007433 A JP 2012007433A JP 6267412 B2 JP6267412 B2 JP 6267412B2
- Authority
- JP
- Japan
- Prior art keywords
- camp
- extract
- production
- mixed
- mass
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000003491 cAMP production Effects 0.000 title description 9
- 239000003112 inhibitor Substances 0.000 title 1
- 239000010330 ougon Substances 0.000 claims description 14
- 230000002401 inhibitory effect Effects 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 3
- 241000207923 Lamiaceae Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000469 ethanolic extract Substances 0.000 claims 1
- 239000000284 extract Substances 0.000 description 28
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 19
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 19
- 229940095074 cyclic amp Drugs 0.000 description 19
- 238000004519 manufacturing process Methods 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000003814 drug Substances 0.000 description 11
- 235000019441 ethanol Nutrition 0.000 description 11
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 10
- -1 aliphatic ketones Chemical class 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 238000000605 extraction Methods 0.000 description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 229940058015 1,3-butylene glycol Drugs 0.000 description 5
- 235000019437 butane-1,3-diol Nutrition 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 230000008591 skin barrier function Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010003645 Atopy Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 235000014214 soft drink Nutrition 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000008309 hydrophilic cream Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- 241000317410 Arisaema dracontium Species 0.000 description 1
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 229940121946 Cyclic AMP inhibitor Drugs 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 241000723267 Diospyros Species 0.000 description 1
- 235000002239 Dracunculus vulgaris Nutrition 0.000 description 1
- 102100028314 Filaggrin Human genes 0.000 description 1
- 101710088660 Filaggrin Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000007390 Glycogen Phosphorylase Human genes 0.000 description 1
- 108010046163 Glycogen Phosphorylase Proteins 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 1
- 229940015301 baicalein Drugs 0.000 description 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 1
- 229960003321 baicalin Drugs 0.000 description 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 1
- 150000008107 benzenesulfonic acids Chemical class 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000002430 glycogenolytic effect Effects 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Description
皮膚外用剤、化粧料にも用いられ、特許文献4ではストレス性の肌荒れ予防改善効果が、特許文献5ではフィラグリン産生促進効果が知られているが、cAMP産生抑制効果については知られていなかった。
特許文献2 特開平07−238066号
特許文献3 特開2002−029959号
特許文献4 特開2005−170840号
特許文献5 特開2006−016337号
使用する前記オウゴンの部位としては、特に制限はなく、目的に応じて適宜選択することができるが、例えば、葉、茎、根、花、蕾、種子、果実、果皮、果核、地上部、全草、これらの混合物などが挙げられ、これらの中でも、根が好ましい。
細切りにしたオウゴンの根乾燥物100gにエチルアルコール500mLを加え、還流抽出器で80℃にて2時間加熱抽出し、熱時濾過した。残渣についてさらに同様の抽出処理を行い、得られた抽出液を合わせて減圧下に濃縮し、乾燥して、オウゴン抽出物9gを得た。
細切りにしたオウゴン全草乾燥物100gに50質量%の1,3−ブチレングリコール(水と1,3−ブチレングリコールとの質量比=1:1)500mLを加え、還流抽出器で80℃にて2時間加熱抽出し、熱時濾過した。残渣についてさらに同様の抽出処理を行い、得られた抽出液を合わせて減圧下に濃縮し、乾燥して、オウゴン抽出物9gを得た。
細切りにしたオウゴン地上部乾燥物100gに精製水500mLを加え、還流抽出器で80℃にて2時間加熱抽出し、熱時濾過した。残渣についてさらに同様の抽出処理を行い、得られた抽出液を合わせて減圧下に濃縮し、乾燥して、オウゴン抽出物5gを得た。
正常ヒトメラノサイトを使用し、オウゴンエキス(一丸ファルコス株式会社製)を検体として、細胞内cAMP量抑制効果を調べた。本オウゴンエキスはオウゴンの周皮を除いた根を70%エチルアルコール水溶液に3日間浸漬後、ろ過したろ液を用いている。
正常ヒトメラノサイトをBPE非含有のMediumu254培地(倉敷紡績株式会社製)で二酸化炭素濃度5v/v%環境下において37℃にて二日間培養した。その後オウゴンエキスを10%エチルアルコール溶液に溶解し、その最終濃度が0μg/mL(対照)、125μg/mL、500μg/mLとなるように溶液を作製し培養液に添加した。さらに翌日培地交換を行い、培養液に前回の半量のオウゴン溶液を添加し、さらに3−isobuthyl−1−methylxanthine(和光純薬工業株式会社製)のDMSO溶液を終濃度が0.1mmol/Lとなるように添加した後、37℃で90分間静置した。
次に培地を除去し、PBSを用いて全てのウェルを洗浄し、細胞内cAMPを抽出するため氷冷した65%エチルアルコールを添加し、細胞を破砕した後、不要な沈殿を除去し、cAMP溶液を得た。次に遠心エバポレーターを用いて窒素気流下、60℃で乾固物を得た。さらにcAMP測定キット(GEヘルスケア バイオサイエンス株式会社製)の定法に従いOD450を測定し、cAMP量を測定した。結果を図1に示す。
オウゴンエキスは濃度依存的にcAMP量を抑制した。
(成分) (質量%)
1.モノステアリン酸ポリオキシエチレン
(20E.O.)ソルビタン
1.0
2.トリオレイン酸ポリオキシエチレン
(20E.O.)ソルビタン
0.5
3.グリセリルモノステアレート 1.5
4.ステアリン酸 0.5
5.ベヘニルアルコール 0.5
6.スクワラン 8.0
7.カルボキシビニルポリマー 0.1
8.パラオキシ安息香酸メチル 0.1
9.水酸化ナトリウム 0.05
10.精製水 残量
11.製造例1のオウゴン抽出物 0.03
12.エチルアルコール 5.0
13.香料 0.05
A:成分1〜6を70℃で均一に混合溶解する。
B:成分7〜10を均一溶解し、70℃に加熱する。
C:AにBを加えて乳化する。
D:室温まで冷却後、成分11〜13を加えて均一に混合し乳液を得た。
(成分) (質量%)
1.ステアリン酸 18
2.セタノール 4
3.酢酸dl−α―トコフェロール 0.2
4.トリエタノールアミン 2.5
5.グリセリン 5.0
6.グリチルリチン酸ジカリウム 0.5
7.製造例2のオウゴン抽出物 5.0
8.パラオキシ安息香酸メチル 0.1
9.精製水 残量
A.成分1〜3を加熱混合し、75℃に保つ。
B.成分4〜9を混合し、75℃に保つ。
C.AにBを徐々に加え、軟膏剤を得た。
(成分) (質量%)
1.モノラウリン酸ポリオキシエチレン
(20E.O.)ソルビタン
1.2
2.エチルアルコール 8.0
3.パラオキシ安息香酸エチル 0.1
4.グリセリン 5.0
5.1,3−ブチレングリコール 6.5
6.製造例3のオウゴン抽出物 0.1
7.精製水 残量
A.成分1〜3を混合溶解する。
B.成分4〜7を混合溶解する。
C.AとBを混合して均一にし、ローション剤を得た。
(成分) (質量%)
1.1,3―ブチレングリコール 5.0
2.水素添加大豆リン脂質 0.5
3.酸化チタン 5.0
4.ベンガラ 0.1
5.黄酸化鉄 1.0
6.黒酸化鉄 0.05
7.ステアリン酸 0.9
8.モノステアリン酸グリセリン 0.3
9.セトステアリルアルコール 0.4
10.モノオレイン酸ポリオキシエチレン(20E.O.)ソルビタン 0.2
11.トリオレイン酸ポリオキシエチレン(20E.O.)ソルビタン 0.2
12.パラメトキシケイ皮酸2―エチルヘキシル 5.0
13.アクリル酸・メタクリル酸アルキル共重合体(注1) 0.5
14.トリエタノールアミン 1.5
15.グリセリン 5.0
16.フェノキシエタノール 0.3
17.精製水 残量
18.製造例1のオウゴン抽出物 0.1
19.香料 0.02
(注1)ペミュレンTR−2(NOVEON社製)
A:成分1〜6を分散する。
B:Aに成分7〜12を加え70℃で均一に混合する。
C:成分13〜17を70℃で均一に混合する。
D:CにBを加え乳化し、室温まで冷却する。
E:Dに成分18、19を添加し均一に混合して水中油型クリーム状リキッドファンデーションを得た。
(成分) (質量%)
1.乳糖 24.0
2.結晶セルロース 20.0
3.コーンスターチ 15.0
4.製造例2のオウゴン抽出物 5.0
5.グリセリン脂肪酸エステル 5.0
6.二酸化ケイ素 1.0
7.デキストリン 残量
(成分) (質量%)
1.果糖ブドウ糖液糖 30.0
2.乳化剤 0.5
3.製造例3のオウゴン抽出物 1.0
4.香料 適量
5.精製水
残量
Claims (1)
- シソ科コガネバナ属オウゴンの70%エタノール水溶液抽出物を有効成分として用いることを特徴とする、cAMP上昇抑制方法(ヒトに対する医療行為を除く。)。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012007433A JP6267412B2 (ja) | 2012-01-17 | 2012-01-17 | cAMP産生抑制剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012007433A JP6267412B2 (ja) | 2012-01-17 | 2012-01-17 | cAMP産生抑制剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013147438A JP2013147438A (ja) | 2013-08-01 |
JP6267412B2 true JP6267412B2 (ja) | 2018-01-24 |
Family
ID=49045319
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012007433A Active JP6267412B2 (ja) | 2012-01-17 | 2012-01-17 | cAMP産生抑制剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6267412B2 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016193863A (ja) * | 2015-03-31 | 2016-11-17 | 小林製薬株式会社 | セマフォリン3a遺伝子発現増強剤、及びセマフォリン3aタンパク産生亢進剤 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61161219A (ja) * | 1985-01-08 | 1986-07-21 | Osaka Chem Lab | アトピ−性皮膚炎症用化粧料組成物 |
JPH07238066A (ja) * | 1994-02-28 | 1995-09-12 | Green Cross Corp:The | ベンゼンスルホン酸誘導体、その製造法およびその用途 |
US5919436A (en) * | 1997-09-25 | 1999-07-06 | The Board Of Regents Of The University Of Oklahoma | Method of lightening skin |
JP2000169383A (ja) * | 1998-12-07 | 2000-06-20 | Ichimaru Pharcos Co Ltd | 抗アレルギー剤 |
JP2001288066A (ja) * | 2000-03-31 | 2001-10-16 | Shiseido Co Ltd | 皮膚バリアー機能改善剤 |
JP2004175687A (ja) * | 2002-11-25 | 2004-06-24 | Shiseido Co Ltd | 皮膚バリアー機能回復促進剤 |
JP2004359571A (ja) * | 2003-06-03 | 2004-12-24 | Shiseido Co Ltd | サイクリックAMP(cAMP)産生阻害剤 |
JP2005298450A (ja) * | 2004-04-15 | 2005-10-27 | Taisho Pharmaceut Co Ltd | 更年期症候群の予防又は治療剤組成物 |
JP2006316029A (ja) * | 2005-05-16 | 2006-11-24 | Maruzen Pharmaceut Co Ltd | エンドセリン−1産生抑制剤及びメラニン産生抑制剤 |
KR20100009151A (ko) * | 2008-07-18 | 2010-01-27 | 한국화학연구원 | 삼백초와 황금의 혼합 추출물을 유효성분으로 함유하는골다공증 예방 또는 치료용 조성물 |
-
2012
- 2012-01-17 JP JP2012007433A patent/JP6267412B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2013147438A (ja) | 2013-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6054700B2 (ja) | 脱糖化剤及び皮膚外用剤 | |
JP2009107983A (ja) | メイラード反応阻害剤並びに抗老化剤及び皮膚外用剤 | |
KR101794006B1 (ko) | 식물 추출물을 포함하는 염증 개선용 조성물 | |
JP5557414B2 (ja) | 保湿剤、細胞賦活剤、及び美白剤 | |
KR101799155B1 (ko) | 한방 복합추출물을 유효성분으로 함유하는 피부개선용 외용제 조성물 | |
JP6636467B2 (ja) | 紅葉した大豆の葉の抽出物を含む組成物およびその製造方法 | |
JP2014185100A (ja) | Age産生抑制剤 | |
JP6267412B2 (ja) | cAMP産生抑制剤 | |
JP2011068583A (ja) | タンパク質糖化抑制剤 | |
WO2008018118A1 (fr) | Composition contenant du nemagaritake et un agent hydratant, un stimulant cellulaire, un agent de blanchiment et un anti-oxydant | |
JP6629271B2 (ja) | Endo180産生促進剤 | |
JP5896618B2 (ja) | メラニン産生抑制剤 | |
JP5294847B2 (ja) | 保湿剤、美白剤及び痩身剤 | |
JP4021363B2 (ja) | 皮膚外用剤 | |
JP4748962B2 (ja) | 保湿剤、細胞賦活剤、美白剤、及び抗酸化剤 | |
KR102673345B1 (ko) | 병풀, 컴프리, 및 수국 추출물을 포함하는 피부 개선용 조성물 | |
JP5993724B2 (ja) | エラスチン産生促進剤及び皮膚化粧料 | |
JP5412798B2 (ja) | 最終糖化産物の生成抑制剤、化粧料および飲食品 | |
KR100808418B1 (ko) | 피부 수렴효과를 갖는 아선약, 계피, 지유, 연꽃, 제라늄추출물을 함유하는 화장료 조성물 | |
JP4994684B2 (ja) | 保湿剤、細胞賦活剤、及び抗酸化剤 | |
WO2008035572A1 (fr) | Agent hydratant, agent anti-vieillissement, agent blanchissant la peau et agent anti-oxydant | |
KR102026343B1 (ko) | 명아주 추출물 및 참마 추출물을 포함하는 화장료 조성물 및 이의 제조방법 | |
JP6601959B2 (ja) | 皮膚外用剤 | |
JP6385533B2 (ja) | リパーゼ阻害剤および皮脂分解抑制用皮膚化粧料 | |
JP2007051163A (ja) | コラーゲン産生促進剤並びに皮膚化粧料及び美容用飲食品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150106 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20150106 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150929 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151013 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151211 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160510 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160810 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20160818 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20160909 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6267412 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |